MDMA, also known as ecstasy or molly, gained notoriety in the Bay Area after chemist Sasha Shulgin introduced it to therapist Leo Zeff in 1977, who promoted its therapeutic benefits. The drug later attracted public attention and was classified as Schedule One by the DEA in 1985, limiting research. Recent years, however, have seen increased scientific inquiry into MDMA, particularly regarding its therapeutic applications in PTSD treatment, exemplified by Lykos Therapeutics seeking FDA approval following successful Phase 3 trials.
Gül Dölen's research at UC Berkeley's Center for the Science of Psychedelics focuses on MDMA and critical periods of brain development, utilizing mice and octopuses.
Jennifer Mitchell led the phase 3 trials of Lykos Therapeutics' study on MDMA-assisted therapy for PTSD, marking the largest studies of MDMA's therapeutic applications.
Rachel Nuwer’s book, I Feel Love, chronicles the history of MDMA, detailing its evolution from a German patent to current research and advocacy efforts.
MDMA was classified as Schedule One by the DEA in 1985 due to its high potential for abuse, halting its medical research until recent interest surged.
Collection
[
|
...
]